Hepatocellular carcinoma is the third common cause of mortality worldwide with major
changes of the prevalence of different etiologies. Nowadays we found more conflicting data
about metabolic dysfunction -associated fatty liver disease (MAFLD) and its effect on a major
spectrum of liver diseases as an increasing cause of hepatocellular carcinoma worldwide.
The study was to assessed prevalence of MAFLD as a single causes of HCC among HCC
patients presented to the Hepatoma specialized outpatient clinic and to evalute effect on tumor
burden and survival as compared to HCV infection patients related HCC.
Twenty nine patients with MAFLD related HCC were included in group A while 58 patients
with HCV related HCC were enrolled as group B .In group (A) ; the mean age was 58.86
(+8.47) years, this group included 20 male patients (68.97%) and 9 female patients (31.03%).
While in group (B); the mean age was 60/05(+ 6.83) years, with 45 males (77.59%) and 13 females
(22.41%) without significant difference between both as to age (P=0.482) or sexes
(P=0.383). In the MAFLD related HCC group there were 19 /29 patients (65.5%) had Diabetes
mellitus, 15 patients (51.7%) had hypertension and 9 patients (31%) were on antidyslipidimic
drugs. The mean Body mass index (BMI) was 29kg/m2 (±SD 2.81) Also, comparison between
groups regarding tumor burden and characteristics of HCC, Child Pugh score, or Barcelona
clinic liver cancer (BCLC ) showed no significant statistical difference between both groups
except for lymph node metastases which was higher in patients with HCV related HCC.
One year survival rate was higher in MAFLD group (72.4%) than of that in HCV related HCC
group (58.6%) however, no significant statistical difference between both groups p=0.184